Page 1 | Search Results | Blood | American Society of Hematology

1-19 of 19

Sort by

Sort Order Select

Journal Articles

Belantamab Mafodotin in Combination with Lenalidomide Plus Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: Safety and Efficacy Analysis of DREAMM-6 Trial Arm-a

Rakesh Popat, Bradley Augustson, Mercedes Gironella, Cindy Lee, Paul Cannell, Nashita Patel, Ravi Kasinathan, Rachel Rogers, Amy Curry, Fernando Carreno, Sumita Roy-Ghanta, Joanna Opalinska, Hang Quach

Blood (2023) 142 (Supplement 1): 2010.

https://doi.org/10.1182/blood-2023-178044

Published: 2023

Journal Articles

Preliminary Safety and Efficacy of Bgb-11417, a Novel Bcl-2 Inhibitor, in Combination with Azacitidine in Patients with Acute Myeloid Leukemia (AML)

Blood (2022) 140 (Supplement 1): 3329–3332.

https://doi.org/10.1182/blood-2022-166937

Published: 2022

Journal Articles

Blinatumomab Alternating With Low-Intensity Chemotherapy (CT) Treatment for Older Adults With Newly Diagnosed Philadelphia (Ph)-Negative B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL) is Well Tolerated and Efficacious: Safety Run-In Results for the Phase 3 Randomized Controlled Golden Gate Study

Elias Jabbour, Ibrahim Aldoss, Shaun Fleming, Ashish Bajel, Paul Cannell, Monika Brüggemann, Gerhard Zugmaier, Joan Morris, Yuqi Chen, Sonny Powar, Hansen Wong, Björn Steffen, Hagop Kantarjian, Nicola Goekbuget

Blood (2022) 140 (Supplement 1): 6134–6136.

https://doi.org/10.1182/blood-2022-156080

Published: 2022

Journal Articles

Disease Burden Subgroup Analysis of Health-Related Quality of Life of Blinatumomab Versus Standard-of-Care Chemotherapy in Patients with Relapsed or Refractory Philadelphia Chromosome-Negative B-Cell Precursor Acute Lymphoblastic Leukemia in a Randomized, Open-Label Phase 3 Study (TOWER)

Anthony S. Stein, MD, Zachary F. Zimmerman, Paul Cannell, Hervé Dombret, Johan Maertens, MD, Max S. Topp, Janet L. Franklin, Ze Cong, PhD MS, Xinke Zhang, Yan Li, Andre Schuh

Blood (2018) 132 (Supplement 1): 3967.

https://doi.org/10.1182/blood-2018-99-115160

Published: 2018

Journal Articles

Age Subgroup Analysis of Health-Related Quality of Life of Blinatumomab Versus Standard-of-Care Chemotherapy in Patients with Relapsed or Refractory Philadelphia Chromosome-Negative B-Cell Precursor Acute Lymphoblastic Leukemia in a Randomized, Open-Label, Phase 3 Study (TOWER)

Max S. Topp, Zachary F. Zimmerman, Paul Cannell, Hervé Dombret, Johan Maertens, MD, Anthony S. Stein, MD, Janet L. Franklin, Ze Cong, PhD MS, Xinke Zhang, Andre Schuh

Blood (2018) 132 (Supplement 1): 5165.

https://doi.org/10.1182/blood-2018-99-115123

Published: 2018

Journal Articles

Health-related quality of life in adults with relapsed/refractory acute lymphoblastic leukemia treated with blinatumomab

Max S. Topp, Zachary Zimmerman, Paul Cannell, Hervé Dombret, Johan Maertens, Anthony Stein, Janet Franklin, Qui Tran, Ze Cong, Andre C. Schuh

Blood (2018) 131 (26): 2906–2914.

https://doi.org/10.1182/blood-2017-09-804658

Published: 2018

Includes: Supplemental data

Journal Articles

Health-Related Quality of Life in Adults Treated with Blinatumomab Using the Acute Lymphoblastic Leukemia Symptom Scale

Max S. Topp, MD, Zachary F. Zimmerman, MD PhD, Paul Cannell, MD, Herve Dombret, MD, Anthony S. Stein, MD, Janet Franklin, MD MPH, Kun Nie, PhD, Ze Cong, PhD, Andre Schuh, MD FRCPC

Blood (2017) 130 (Supplement 1): 2571.

https://doi.org/10.1182/blood.V130.Suppl_1.2571.2571

Published: 2017

Journal Articles

Maintenance Therapy with Blinatumomab in Adults with Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (ALL): Overall Survival in Adults Enrolled in a Phase 3 Open-Label Trial

Alessandro Rambaldi, MD Prof, Françoise Rigal-Huguet, MD, Pavel Zak, Paul Cannell, MD, Kun Nie, PhD, Zachary F. Zimmerman, MD PhD, Max S. Topp, MD

Blood (2017) 130 (Supplement 1): 2552.

https://doi.org/10.1182/blood.V130.Suppl_1.2552.2552

Published: 2017

Journal Articles

Randomized Phase III Study (ADMYRE) of Plitidepsin in Combination with Dexamethasone Vs. Dexamethasone Alone in Patients with Relapsed/Refractory Multiple Myeloma

Blood (2017) 130 (Supplement 1): 1886.

https://doi.org/10.1182/blood.V130.Suppl_1.1886.1886

Published: 2017

Journal Articles

Increased Idarubicin Dosage during Consolidation Therapy for Adult Acute Myeloid Leukemia Improves Leukemia-Free Survival

Bradstock Kenneth, Emma Link, DPhil, Juliana Di Iulio, BAppSc, PhD, Jeff Szer, MB, BS, FRACP, Paula Marlton, MBBS, FRCPA, FRACP, Andrew Wei, MBBS, PhD, Arno Enno, MB,BS,FRCPA, FRACP, Anthony P Schwarer, MD MBBS (Hons), FRACP, FRCPA, Ian D. Lewis, MBBS PhDFRACP FRCPA, James D'Rozario, MB BS FRACP, Luke Coyle, MBBS, FRACP, FRCPA, Gavin Cull, MBBS DM FRACP FRCPA, Philip Campbell, MB ChB FRACP FRCPA, Michael Francis Leahy, FRACP, Uwe H Hahn, MDFGCP FRCPA, Paul Cannell, MD, Campbell Tiley, MBBS,FRACP, FRCPA, Raymond M. Lowenthal, MD FRACP, FRCP, John Moore, MBBS, MD FRACP , FRCPA, Kimberly Cartwright, FRACP,MDFRCPA, Ilona Cunningham, John Taper, MBBS FRACP FRCPA, Andrew Grigg, MBBS, MD FRACP, FRCPA, Andrew W. Roberts, MBBS PhD, Warwick John Benson, Mark S Hertzberg, MBBS PhDFRACP FRCPA, Sandra F. Deveridge, MDBSc,FRACP,FRCPA, Philip Arthur Rowlings, FRACP,FRCPA,MBBS,MS, Anthony K. Mills, MBBS, FRACP, FRCPA, Devinder S Gill, MBChB FRCPath MRCP, Peter G Bardy, MBBS, FRACP, FRCPA, Lynda Campbell, John F. Seymour, MD

Blood (2016) 128 (22): 338.

https://doi.org/10.1182/blood.V128.22.338.338

Published: 2016

Journal Articles

Health-Related Quality of Life (HRQoL) of Blinatumomab Versus Standard of Care (SOC) Chemotherapy in Patients with Relaspsed or Refractory Philadelphia Negative B-Cell Precursor Acute Lymphoblastic Leukemia in a Randomized, Open-Label Phase 3 Study (TOWER)

Max S Topp, MD, Zachary Zimmerman, MD PhD, Paul Cannell, MD, Hervé Dombret, MD PhD, Johan Maertens, MD PhD, Andre C. Schuh, MD FRCPC, Janet Franklin, MD MPH, Kun Nie, PhD, Ze Cong

Blood (2016) 128 (22): 222.

https://doi.org/10.1182/blood.V128.22.222.222

Published: 2016

Journal Articles

Lower Dose Lenalidomide and Dexamethasone for Patients with Relapsed/Refractory Multiple Myeloma Who Are Aged 60 Years or over and/or at Risk of Myelosuppression: Final Analysis of the Revlite Trial and Matched Comparison to the MM009 and MM010 Trials

Hang Quach, MD, Simon Harrison, MD, Liam J. Fernyhough, MB, BS, BMedSci, Ross Alistair Henderson, PhD FRACP, FRCPA, Gillian Corbett, MDFRACP FRCPA, Peter Browett, MBChB, FRACP, FRCPA, Hilary Anne Blacklock, FRACP, Craig Underhill, MD, Paul Cannell, MD, Judith Trotman, MBChB, Emma Link, Linda Cowan, Jack S Li, Meletios A. Dimopoulos, H. Miles Prince, MD

Blood (2015) 126 (23): 4236.

https://doi.org/10.1182/blood.V126.23.4236.4236

Published: 2015

Journal Articles

Marizomib Overcomes Compensatory Hyperactivation of Trypsin-like and Caspase-like Subunits to Provide Pan-Proteasome Subunit Inhibition in Patients with Multiple Myeloma and Solid Tumors

Andrew Spencer, Simon Harrison, MD, Francis Burrows, Paul Mainwaring, MD, Timothy Price, MD, Michael J Millward, MD, Peeter Padrik, MD, Craig Underhill, MD, Paul Cannell, MD, Steven D Reich, MD, Mohit Trikha, PhD

Blood (2015) 126 (23): 5375.

https://doi.org/10.1182/blood.V126.23.5375.5375

Published: 2015

Journal Articles

Outcomes After Unrelated Cord Blood Transplantation For Adults With Primary Or Secondary Myelofibrosis: A Retrospective Study On Behalf Of Eurocord and Chronic Malignancy Working Party-EBMT

Blood (2013) 122 (21): 2156.

https://doi.org/10.1182/blood.V122.21.2156.2156

Published: 2013

Journal Articles

SAR245409 Monotherapy In Relapsed/Refractory Follicular Lymphoma: Preliminary Results From The Phase II ARD12130 Study

Blood (2013) 122 (21): 86.

https://doi.org/10.1182/blood.V122.21.86.86

Published: 2013

Journal Articles

A Phase II Study of Risk-Adapted Intravenous Melphalan in Patients with AL Amyloidosis,

Peter Mollee, MBBS, FRCPA, FRACP, MMSc, Campbell Tiley, MBBS, FRACP, FRCPA, Ilona Cunningham, John Moore, Miles Prince, MD, FRACP, FRCPA, Paul Cannell, MBBS, FRCPA, FRACP, Steve Gibbons, FRCPA, FRACP, MB, CHB, Jill Tate, BSc, MSc, FFSc, Sanjoy Paul, PhD, MSc, Devinder S Gill, MD

Blood (2011) 118 (21): 3973.

https://doi.org/10.1182/blood.V118.21.3973.3973

Published: 2011

Journal Articles

A Retrospective Analysis of 344 Fludarabine Melphalan RIC Allogeneic Stem Cell Transplants for Myeloid and Lymphoid Malignancies In Australia and New Zealand 1998–2008,

Adam J Bryant, Elango Pillai, Glen Kennedy, Anna Kalff, David Ritchie, Biju George, Mark Hertzberg, Sushrut S. Patil, FRACP FRCPA, Andrew Spencer, MD, Keith Fay, Paul Cannell, Leanne Berkahn, Richard Doocey, Ruth Spearling, Ian Nivison-Smith, John Moore

Blood (2011) 118 (21): 4143.

https://doi.org/10.1182/blood.V118.21.4143.4143

Published: 2011

Journal Articles

Phase 1 Clinical Evaluation of Twice-Weekly Marizomib (NPI-0052), a Novel Proteasome Inhibitor, in Patients with Relapsed/Refractory Multiple Myeloma (MM)

Paul G. Richardson, MD, Andrew Spencer, MD, Paul Cannell, MBBS, FRCPA, FRACP, Simon J. Harrison, MBBS MRCP (uk) MRCPath (uk) PhD, Laurence Catley, MBBS, FRCPA, FRACP, Craig Underhill, MBBS, FRACP, Todd M. Zimmerman, MD, Craig C. Hofmeister, MD, Andrzej J Jakubowiak, MD, PhD, Jacob P. Laubach, MD, Michael A. Palladino, PhD, Angie M. Longenecker, RN, BSN, Ana Lay, Sandra Wear, RN, G. Kenneth Lloyd, PhD, Alison L. Hannah, MD, Steve Reich, MD, Matthew A. Spear, MD, Kenneth C. Anderson, MD

Blood (2011) 118 (21): 302.

https://doi.org/10.1182/blood.V118.21.302.302

Published: 2011

Journal Articles

A randomized trial of high-versus conventional-dose cytarabine in consolidation chemotherapy for adult de novo acute myeloid leukemia in first remission after induction therapy containing high-dose cytarabine

Blood (2005) 105 (2): 481–488.

https://doi.org/10.1182/blood-2004-01-0326

Published: 2005

NARROW

Belantamab Mafodotin in Combination with Lenalidomide Plus Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: Safety and Efficacy Analysis of DREAMM-6 Trial Arm-a

Preliminary Safety and Efficacy of Bgb-11417, a Novel Bcl-2 Inhibitor, in Combination with Azacitidine in Patients with Acute Myeloid Leukemia (AML)

Disease Burden Subgroup Analysis of Health-Related Quality of Life of Blinatumomab Versus Standard-of-Care Chemotherapy in Patients with Relapsed or Refractory Philadelphia Chromosome-Negative B-Cell Precursor Acute Lymphoblastic Leukemia in a Randomized, Open-Label Phase 3 Study (TOWER)

Age Subgroup Analysis of Health-Related Quality of Life of Blinatumomab Versus Standard-of-Care Chemotherapy in Patients with Relapsed or Refractory Philadelphia Chromosome-Negative B-Cell Precursor Acute Lymphoblastic Leukemia in a Randomized, Open-Label, Phase 3 Study (TOWER)

Health-related quality of life in adults with relapsed/refractory acute lymphoblastic leukemia treated with blinatumomab

Health-Related Quality of Life in Adults Treated with Blinatumomab Using the Acute Lymphoblastic Leukemia Symptom Scale

Maintenance Therapy with Blinatumomab in Adults with Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (ALL): Overall Survival in Adults Enrolled in a Phase 3 Open-Label Trial

Randomized Phase III Study (ADMYRE) of Plitidepsin in Combination with Dexamethasone Vs. Dexamethasone Alone in Patients with Relapsed/Refractory Multiple Myeloma

Increased Idarubicin Dosage during Consolidation Therapy for Adult Acute Myeloid Leukemia Improves Leukemia-Free Survival

Health-Related Quality of Life (HRQoL) of Blinatumomab Versus Standard of Care (SOC) Chemotherapy in Patients with Relaspsed or Refractory Philadelphia Negative B-Cell Precursor Acute Lymphoblastic Leukemia in a Randomized, Open-Label Phase 3 Study (TOWER)

Lower Dose Lenalidomide and Dexamethasone for Patients with Relapsed/Refractory Multiple Myeloma Who Are Aged 60 Years or over and/or at Risk of Myelosuppression: Final Analysis of the Revlite Trial and Matched Comparison to the MM009 and MM010 Trials

Marizomib Overcomes Compensatory Hyperactivation of Trypsin-like and Caspase-like Subunits to Provide Pan-Proteasome Subunit Inhibition in Patients with Multiple Myeloma and Solid Tumors

Outcomes After Unrelated Cord Blood Transplantation For Adults With Primary Or Secondary Myelofibrosis: A Retrospective Study On Behalf Of Eurocord and Chronic Malignancy Working Party-EBMT

SAR245409 Monotherapy In Relapsed/Refractory Follicular Lymphoma: Preliminary Results From The Phase II ARD12130 Study

A Phase II Study of Risk-Adapted Intravenous Melphalan in Patients with AL Amyloidosis,

A Retrospective Analysis of 344 Fludarabine Melphalan RIC Allogeneic Stem Cell Transplants for Myeloid and Lymphoid Malignancies In Australia and New Zealand 1998–2008,

Phase 1 Clinical Evaluation of Twice-Weekly Marizomib (NPI-0052), a Novel Proteasome Inhibitor, in Patients with Relapsed/Refractory Multiple Myeloma (MM)

A randomized trial of high-versus conventional-dose cytarabine in consolidation chemotherapy for adult de novo acute myeloid leukemia in first remission after induction therapy containing high-dose cytarabine

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only